Video

2022 AUA preview: Dr. Pearlman on top research in sexual dysfunction and infertility

Author(s):

Urology Times staff

Amy M. Pearlman, MD, highlights 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Amy M. Pearlman, MD, discusses 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting. Pearlman is a clinical assistant professor and Men's Health Program Director at the University of Iowa, Iowa City.

      The following 6 abstracts are previewed:

      LBA02-09 (Hallak, et al): Intracellular SARS-COV-2 Found In The Spermatozoa Of Convalescent Men With Negative Pcr Semen Samples Revealed By Electron Microscopy

      LBA02-11 (Shechter, et al): Novel On-Demand Treatment For Lifelong Premature Ejaculation Using Transcutaneous Perineal Mini-Patch Stimulator

      PD09-05 (Marinaro, et al): Use of Fresh Ejaculated Semen Samples on the Day of Planned mTESE in Men with "Azoospermia"

      MP21-02 (Flores, et al): Predictors of Corporo-Venocclusive Dysfunction (CVOD) in Men With Bilateral Nerve-Sparing Radical Prostatectomy (RP)

      PD23-01 (Tyler, et al): Improved Peyronie's Disease Curvature Outcomes Using a More Aggressive Collagenase Technique

      MP34-02 (Able, et al): Opioid Prescribing Following Male Infertility Surgery is Associated with Persistent Opioid Use - Analysis of a U.S. Claims Database

      Related Videos
      5 key trial insights from AUA 2025
      5 key trial insights from AUA 2025
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
      Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
      Alexander Glaser, MD, on real-world outcomes with Aquablation
      Alexander Glaser, MD, on real-world outcomes with Aquablation
      Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
      Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
      Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
      John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
      John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
      Related Content
      Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
      May 5th 2025

      AUA 2025 recap: Urologic oncology trials in progress

      Hannah Clarke
      Take a look through some of the notable studies that were spotlighted during this year’s meeting.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
      May 2nd 2025

      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

      Hannah Clarke
      Data showed an overall CR rate of 82.4%.
      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
      April 30th 2025

      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

      Amy M. Pearlman, MD Ryan Terlecki, MD
      A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
      April 30th 2025

      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

      Hannah Clarke
      Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      © 2025 MJH Life Sciences

      All rights reserved.